By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Amorcyte Inc. 

4 Pearl Court
Suite C
Allendale  New Jersey  07401  U.S.A.
Phone: 908-510-0617 Fax: n/a




Company News
NeoStem, Inc. Subsidiary, Amorcyte Inc., Announces Significant Expansion in Its Claims Granted to Protect the Use of CD34+ Cells 9/10/2012 9:08:27 AM
Amorcyte Inc., a NeoStem, Inc. Company, Enrolls First Patient in PreSERVE Phase 2 Trial for Acute Myocardial Infarction 1/25/2012 10:47:43 AM
Amorcyte Inc., a NeoStem, Inc. Company, Announces Expansion of Intellectual Property Coverage 1/10/2012 10:17:59 AM
NeoStem, Inc. Closes Amorcyte Inc. Acquisition 10/18/2011 7:00:46 AM
NeoStem, Inc. Provides Update on Amorcyte Inc. Clinical Progress and Reports Results for Second Quarter 8/15/2011 11:24:09 AM
NeoStem, Inc. Signs Definitive Merger Agreement to Acquire Amorcyte Inc. in Equity Transaction 7/15/2011 5:51:00 AM
Amorcyte Inc. Stem Cell Therapy Demonstrates Clinically Significant Reperfusion in Severe Heart Attack Patients 12/21/2010 7:45:57 AM
Amorcyte Inc. Granted Landmark Patent 9/13/2010 9:12:18 AM
Amorcyte Inc. Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at American College of Cardiology Annual Scientific Session 3/30/2009 8:16:06 AM
Amorcyte Inc. Completes Phase I Trial of Stem Cell Therapy for Acute Myocardial Infarction 4/1/2008 11:26:20 AM